Anne Wojciecki to redeem 23andme and its data for $ 305 million

Anne Wojciecki, co-founder and former 23ndme CEO resumed control over a combat genetic test after a new nonprofit organization, research institute, Outbird Regeneron Pharmaceuticalscampaign announced Friday.

TTAM will receive virtually all 23and assets for $ 305 million, including its personal services and research services, as well as a subsidiary of Lemonaid Health. This is a great victory for Wojcicki, who left the role of CEO when 23ndme Submitted to section 11 Bankruptcy Protection in March.

Last month, Regeneron announced that he would buy most 23andMe assets for $ 256 after he went out to the top during the bankruptcy auction. But Wojcicki submitted a separate application for $ 305 million via TTAM and pushed the auction. Ttam – This is an abbreviation for the first 23andme letters, reports The Wall Street Journal.

“I am delighted with the fact that the research institute of TTAM will be able to continue the 23andme mission to help people get access, understand and benefit from the human genome,” Wojczitsky said in a statement.

23Andme gained popularity because of its DNA test kits at home, which gave customers understanding their family stories and genetic profiles. Five The CNBC 50 engine campaign went publicly In 2021, with the help of a fusion for the special purpose of the acquisition company. At the peak of 23andme was estimated at about $ 6 billion.

The company struggled to receive repetitive income and endurance viable research and therapeutic Hackers got access to information With almost seven million customers in 2023.

The acquisition of TTAM is still subject to approval by the US bankruptcy court in Missouri.